Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. - Wikidata - wikimedia - TriplyDB

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

http://www.wikidata.org/entity/Q33372613

about

Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy Improved survival with vemurafenib in melanoma with BRAF V600E mutation Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Treatment of metastatic melanoma: an overview Targeting Cell Survival Proteins for Cancer Cell Death Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Melanoma: new insights and new therapies Targeting the Bcl-2 family for cancer therapy Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Inhibition of Mutated, Activated BRAF in Metastatic Melanoma Drug delivery nanoparticles in skin cancers Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts A melanoma molecular disease model A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.Targeted therapy in melanoma.Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Why anti-Bcl-2 clinical trials fail: a solution A phase II trial of sorafenib in metastatic melanoma with tissue correlates.A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.Melanoma: a model for testing new agents in combination therapies.Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1 Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas.Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study.Releasing the brake on the immune system: ipilimumab in melanoma and other tumors Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.The history and future of chemotherapy for melanoma.Current concepts of metastasis in melanoma.

P2860

Q24598856-A52234DF-B2A8-4546-B891-EEEFD1A9FAA6 Q24631953-9B5CB0E6-B4D7-4A75-9937-E15308468529 Q24635408-260AC5FE-E5E0-44BA-B6DD-EB23B15C7893 Q24642384-F576BFA4-7C5C-4389-9898-CC935FD75373 Q26765447-CAEBDBC3-513D-4149-8632-FC03653C943A Q26770492-A8832786-53C7-4E48-8174-0B4AD0AE8DA9 Q26771601-32A4D76A-DAF3-4240-B54B-D6BFA051E461 Q26853127-DD3C46AF-9253-400F-B388-0271B8601AA1 Q26866936-280469CD-EB0C-4F5A-9DF5-E22176673344 Q26996629-9BF03E0F-C9D4-4C20-B49C-4B6E51517600 Q27276774-27D70DB1-373A-41A6-A084-D23BD4FE02B9 Q27860458-3EEF1CAC-04E6-4CB1-93BF-CD1BC00AFF47 Q28390405-76B23197-6509-438A-BA4E-AB887071FE7A Q28538631-8F81BA77-0168-4806-83E3-8651E7651611 Q28741507-294BBDF7-678B-4C43-8F01-53D5A99A6C1B Q33379466-DCD779CF-89A2-4667-AAC6-DF5EA4EE633B Q33383770-99F600E3-9353-4B14-86D7-5CC5DFBDE931 Q33394736-B838C78D-6F26-4966-B231-BC8D00BF4E2E Q33403800-A9C69025-7315-40F0-8219-203A28F63FDA Q33404877-98B37CE4-28EC-49A5-8F16-DE5B3378A5FC Q33573107-F4191CF8-E5E5-4A9D-9DA7-5DBFC30B6EB2 Q33601945-D89BDF50-65C7-4FDC-A7DD-E7CD1DE6F2F2 Q33750205-8C2B8434-2085-4FB1-9F85-A5C62E72822E Q33758493-5CA65A6C-244A-46EE-8B82-F99A497EB3EA Q33785790-314D4C6C-1CE4-45BF-8189-96653BA3F517 Q33797499-4A0BB5D4-2368-4AFC-B7B4-7937E3814AE1 Q33822119-07AA9BAE-B31B-48EA-AB9B-CB25D1111764 Q33863916-CB2D97C7-23DB-4B60-9AE3-827C5F77EB5B Q33994399-F6A1CB0D-075C-4574-AA54-AE8A8BED8105 Q34063991-983D54C8-1918-4875-9284-48613DAFEB5D Q34123184-87566F94-0242-44CF-BDBD-F9974A9638F8 Q34130042-6153DE5D-4A25-4AF7-B690-33B30F7CDF04 Q34213639-A520DF76-0265-4644-B442-FD1017FBE8C4 Q34347631-0235E2E4-546F-4243-892C-63A26EBED683 Q34447732-01C109C6-3CFF-4CD8-B2D7-144FE5A94522 Q34493921-8B50C28C-D8C8-4618-8DA3-82CE07AB7973 Q34497045-14296641-807F-49F8-A3FB-69099FAE9955 Q34515007-974E6592-7226-48E9-830A-CB57BE389FB1 Q34608084-11A557CF-0F43-48D7-8972-189E5DB10BC9 Q34610427-4A90525E-BFC1-4A15-8EB7-5E60452BA5D3

P2860

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

http://www.wikidata.org/entity/Q33372613

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Bcl-2 antisense (oblimersen so ...... limersen Melanoma Study Group.

@ast

Bcl-2 antisense (oblimersen so ...... limersen Melanoma Study Group.

@en

type

label

Bcl-2 antisense (oblimersen so ...... limersen Melanoma Study Group.

@ast

Bcl-2 antisense (oblimersen so ...... limersen Melanoma Study Group.

@en

prefLabel

Bcl-2 antisense (oblimersen so ...... limersen Melanoma Study Group.

@ast

Bcl-2 antisense (oblimersen so ...... limersen Melanoma Study Group.

@en

P1433

Q33372613-2A4C668D-EACB-4DBE-B653-BF013BCCD33D

P1476

Q33372613-15DAAAFF-2351-4158-9C40-17166E99A0A6

P2093

Q33372613-03C08FFF-114E-49E2-B1B3-9533D365D6E7

Q33372613-05FD8B6A-3BC4-46A5-A39D-96B529676B2B

Q33372613-0C965F55-8741-4657-897B-DF8C7C0E7265

Q33372613-4CB2EFE8-AD33-4263-8B7E-0ED0E3529B1E

Q33372613-51B1E65C-2061-4310-A83C-6C55A009FB82

Q33372613-8031FA5C-9098-4C53-96B2-3BBD3D0C7BB8

Q33372613-865FD361-D821-458B-A335-E81908FD607E

Q33372613-8ABFDD53-5B7F-4B16-B614-9CB0F2FD5AA1

Q33372613-A18C0341-25C2-45BC-A38A-5A1716D94600

Q33372613-C05F8677-43AA-4DFD-A0BD-B085EBF98A22

P304

Q33372613-24E3360B-A5A3-442A-9E0D-8C1E15739A9E

P31

Q33372613-1D68C7A6-2701-40D8-BF55-C399923B61B8

P356

Q33372613-8B766483-3223-40BB-A5CA-878D18F8C37D

P407

Q33372613-038D5329-6524-43BA-A724-22F826BF4794

P433

Q33372613-6D714B82-B330-48C0-8A9B-E2097158ED9F

P478

Q33372613-7727B636-2C1F-434A-B99A-1FD5E1FE83F6

P577

Q33372613-2480327C-5C66-4A9D-9CBF-49AA43674C29

P5875

Q33372613-4F141CE6-AB9A-4242-9C16-659F077C30D8

P698

Q33372613-C30A69BF-6E1F-4DED-AC45-E0B7DDF6DE2F

P921

Q33372613-633F9A16-BF94-4A51-9D42-7CBB7E66EDD1

P356

JCO.2006.06.0483

P1433

Journal of Clinical Oncology

P1476

Bcl-2 antisense (oblimersen so ...... limersen Melanoma Study Group.

@en

P2093

Agop Y Bedikian

http://www.w3.org/2001/XMLSchema#string

Anna C Pavlick

http://www.w3.org/2001/XMLSchema#string

Evan M Hersh

http://www.w3.org/2001/XMLSchema#string

Frank G Haluska

http://www.w3.org/2001/XMLSchema#string

Hubert Pehamberger

http://www.w3.org/2001/XMLSchema#string

John M Kirkwood

http://www.w3.org/2001/XMLSchema#string

Martin Gore

http://www.w3.org/2001/XMLSchema#string

Michael Millward

http://www.w3.org/2001/XMLSchema#string

Oblimersen Melanoma Study Group

http://www.w3.org/2001/XMLSchema#string

Peter Hersey

http://www.w3.org/2001/XMLSchema#string

P304

4738-4745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.06.0483

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6823685

http://www.w3.org/2001/XMLSchema#string

P698

16966688

http://www.w3.org/2001/XMLSchema#string

P921